Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE study

The Lancet Haematology

Volumn 3, Issue 5, 2016, Pages e228-e236

  Raskob, Gary ^a   Ageno, Walter ^b   Cohen, Alexander T ^c   Brekelmans, Marjolein P A ^d   Grosso, Michael A ^e   Segers, Annelise ^f   Meyer, Guy ^g   Verhamme, Peter ^h   Wells, Philip S ⁱ   Lin, Min ^e   Winters, Shannon M ^e   Weitz, Jeffrey I ^j   Büller, Harry R ^d  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e DAIICHI SANKYO INC   (United States)

^f ITREAS   (Netherlands)

^g PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^j MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; EDOXABAN; WARFARIN; ANTICOAGULANT AGENT; HEPARIN; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL ASSESSMENT; CREATININE CLEARANCE; DRUG EFFICACY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HEART RIGHT VENTRICLE FUNCTION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROCEDURES; RECURRENT DISEASE; RISK ASSESSMENT; SECONDARY PREVENTION;

ADULT; AGED; ANTICOAGULANTS; COMPARATIVE EFFECTIVENESS RESEARCH; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; PYRIDINES; RECURRENCE; RISK ASSESSMENT; SECONDARY PREVENTION; THIAZOLES; VENOUS THROMBOEMBOLISM; VENTRICULAR DYSFUNCTION, RIGHT; WARFARIN;

EID: 84962563384     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(16)00023-5     Document Type: Article

References (16)

1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e419S-e494S.
2. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014, 35:3145-3146.
3. Kearon C, Akl EA Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 2014, 123:1794-1801.
4. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. Br Med J 2011, 342:d3036.
5. Couturaud F, Sanchez O, Pernod G, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism. The PADIS-PE randomized clinical trial. JAMA 2015, 314:31-40.
6. van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014, 124:1968-1975.
7. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013, 368:709-718.
8. Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013, 369:1406-1415. Hokusai-VTE Investigators.
9. Raskob G, Buller H, Prins M, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-VTE study. J Thromb Haemost 2013, 11:1287-1294.
10. Rosendall FR, Cannegieter SC, van der Meer FJM, Briet E A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69:236-239.
11. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510. The EINSTEIN Investigators.
12. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013, 369:799-808.
13. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
14. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013, 368:699-708.
15. Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297. EINSTEIN-PE Investigators.
16. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e44S-e88S.